BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994;70:487-92. [PMID: 8080735 DOI: 10.1038/bjc.1994.332] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018;109:2841-2851. [PMID: 29945294 DOI: 10.1111/cas.13712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
2 Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998;35:99-103. [PMID: 9463746 DOI: 10.1177/000456329803500113] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 3.5] [Reference Citation Analysis]
3 Tang Z, Fu Y, Ma Z. Multiple signal amplification strategies for ultrasensitive label-free electrochemical immunoassay for carbohydrate antigen 24-2 based on redox hydrogel. Biosens Bioelectron 2017;91:299-305. [PMID: 28033559 DOI: 10.1016/j.bios.2016.12.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
4 Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report. Cancer Biomark 2016;16:537-43. [PMID: 27002756 DOI: 10.3233/CBM-160595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Engaras B, Kewenter J, Nilsson O, Wedel H, Hafstrom L. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. Eur J Surg Oncol. 2001;27:43-48. [PMID: 11237491 DOI: 10.1053/ejso.2000.1027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
6 Yang XQ, Chen C, Peng CW, Liu SP, Li Y. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases. Med Oncol. 2012;29:1030-1036. [PMID: 21553105 DOI: 10.1007/s12032-011-9967-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. [PMID: 17097848 DOI: 10.1016/j.ejso.2006.10.004] [Cited by in Crossref: 467] [Cited by in F6Publishing: 399] [Article Influence: 31.1] [Reference Citation Analysis]
8 Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 2008;62:911-9. [PMID: 18301896 DOI: 10.1007/s00280-007-0672-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
9 Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004;10:427-32. [PMID: 14760772 DOI: 10.3748/wjg.v10.i3.427] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 73] [Article Influence: 5.2] [Reference Citation Analysis]
10 Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci 2019;162:121-40. [PMID: 30905445 DOI: 10.1016/bs.pmbts.2019.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis. 2006;7:170-174. [PMID: 16808798 DOI: 10.1111/j.1443-9573.2006.00263.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
12 Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9. [PMID: 10436809 [PMID: 10436809 DOI: 10.1093/annonc/10.suppl_4.s145] [Cited by in Crossref: 73] [Article Influence: 3.3] [Reference Citation Analysis]
13 Li X, Guo X, Li H, Lin H, Sun Y. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer. Tumor Biol 2014;35:5281-6. [DOI: 10.1007/s13277-014-1687-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 Dou H, Sun G, Zhang L. CA242 as a biomarker for pancreatic cancer and other diseases. Prog Mol Biol Transl Sci. 2019;162:229-239. [PMID: 30905452 DOI: 10.1016/bs.pmbts.2018.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis. 1999;20:362-371. [PMID: 10197444 DOI: 10.1002/(SICI)1522-2683(19990201)20:2%3C362::AID-ELPS362%3E3.0.CO;2-V] [Reference Citation Analysis]
16 Gui JC, Yan WL, Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med. 2014;14:225-233. [PMID: 23456571 DOI: 10.1007/s10238-013-0234-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
17 Qian L, Li Q, Baryeh K, Qiu W, Li K, Zhang J, Yu Q, Xu D, Liu W, Brand RE, Zhang X, Chen W, Liu G. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res 2019;213:67-89. [PMID: 31442419 DOI: 10.1016/j.trsl.2019.08.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
18 Montalto M, Santoro L, Vastola M, Curigliano V, Ricci R, Vecchio FM, Manna R, Gasbarrini G. Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment. Int J Immunopathol Pharmacol 2005;18:603-7. [PMID: 16164842 DOI: 10.1177/039463200501800321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
19 Szajda SD, Waszkiewicz N, Chojnowska S, Zwierz K. Carbohydrate markers of pancreatic cancer. Biochem Soc Trans. 2011;39:340-343. [PMID: 21265800 DOI: 10.1042/bst0390340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
20 Banfi G, Bravi S, Ardemagni A, Zerbi A. CA 19.9, CA 242 and CEA in the Diagnosis and Follow-up of Pancreatic Cancer. Int J Biol Markers 1996;11:77-81. [DOI: 10.1177/172460089601100203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
21 Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:7459-7465. [PMID: 24789274 DOI: 10.1007/s13277-014-1995-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
22 Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63. [PMID: 8853239 DOI: 10.1016/s0960-7404(96)80001-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389. [PMID: 21193998 DOI: 10.1007/s00432-010-0965-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
24 Lennon AM, Goggins M. Diagnostic and Therapeutic Response Markers. Pancreatic Cancer. New York: Springer; 2010. pp. 675-701. [DOI: 10.1007/978-0-387-77498-5_28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
25 Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012;18:2439-51. [PMID: 22372502 DOI: 10.2174/13816128112092439] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
26 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
27 Jiang J, Liu H, Liu Z, Tan S, Wu B. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumor Biol 2015;36:3903-10. [DOI: 10.1007/s13277-014-3033-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
28 Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P, Dietel M. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-40. [DOI: 10.1111/j.1365-2559.1996.tb01396.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
29 Roulston JE. Novel tumour markers: a diagnostic role in pancreatic cancer? Br J Cancer 1994;70:389-90. [PMID: 8080718 DOI: 10.1038/bjc.1994.313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
30 Carpelan-Holmström M, Haglund C, Kuusela P, Järvinen H, Roberts PJ. Preoperative serum levels of CEA and CA 242 in colorectal cancer. Br J Cancer 1995;71:868-72. [PMID: 7710956 DOI: 10.1038/bjc.1995.167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
31 Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362-71. [DOI: 10.1002/(sici)1522-2683(19990201)20:2<362::aid-elps362>3.0.co;2-v] [Cited by in Crossref: 126] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
32 Furuya N, Kawa S, Hasebe O, Tokoo M, Mukawa K, Maejima S, Oguchi H. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer. 1996;73:372-376. [PMID: 8562344 DOI: 10.1038/bjc.1996.63] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
33 Rana S, Dutta U, Kochhar R, Rana SV, Gupta R, Pal R, Jain K, Srinivasan R, Nagi B, Nain CK. Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer. 2012;43:267-271. [PMID: 21573879 DOI: 10.1007/s12029-011-9288-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]